Johnson & Johnson announced the first in-human clinical trial results for the investigational human immunodeficiency virus (HIV-1) preventive vaccine .

Johnson & Johnson announced that the first in-human clinical trial results for the investigational human immunodeficiency virus (HIV-1) preventive vaccine regimen in development at its Janssen Pharmaceutical Companies were presented at the 9th International AIDS Society (IAS) Conference on HIV Science on July 23-26 in Paris, France.

Johnson & Johnson announced encouraging first-in-human clinical data for an investigational HIV-1 vaccine regimen in development at its Janssen Pharmaceutical Companies. In an oral presentation of the early stage Phase 1/IIa APPROACH study at the 9th IAS Conference on HIV Science (IAS 2017), the �mosaic�-based vaccine regimen from Janssen Vaccines & Prevention B.V. (Janssen) appeared to be well-tolerated and elicited HIV-1 antibody responses in 100% of healthy volunteers (n=393). In pre-clinical studies, regimens incorporating mosaic vaccines demonstrated protection against infection with an HIV-like virus.The most effective prime-boost regimen in these studies reduced the per-exposure risk of infection by 94 percent and resulted in 66 percent complete protection after six exposures. Based on immunologic responses observed in APPROACH, as well as protection observed in pre-clinical studies, a lead HIV-1 vaccine regimen comprising Janssen�s Ad26 mosaic candidate and the Clade C gp140 soluble protein has been selected as the basis for further evaluation in a potential Phase IIb proof-of-concept efficacy study. Should this study move forward, Janssen and its global partners anticipate initiating this investigation in southern African countries in late 2017 or early 2018.